Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2012-12-25
- Lead Sponsor
- Intarcia Therapeutics
- Registration Number
- NCT01455922
- Locations
- 🇺🇸
Intarcia Therapeutics, Inc, Hayward, California, United States
A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 460
- Registration Number
- NCT01455857
- Locations
- 🇺🇸
Study Site, Spokane, Washington, United States
🇺🇸Intarcia, Hayward, California, United States
A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650
- First Posted Date
- 2011-10-20
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Intarcia Therapeutics
- Target Recruit Count
- 4156
- Registration Number
- NCT01455896
- Locations
- 🇺🇸
Study SIte, San Diego, California, United States
🇺🇸Study Site, San Antonio, Texas, United States
🇺🇸Intarcia Therapeutics, Inc, Hayward, California, United States
Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 10
- Registration Number
- NCT01444898
- Locations
- 🇺🇸
Children's Hospital of Los Angeles, Los Angeles, California, United States
Study of Comparison the Treatment Effect Between Gastric Bypass and Exenatide in Type 2 Diabetes
- First Posted Date
- 2011-09-19
- Last Posted Date
- 2015-03-27
- Lead Sponsor
- Wu Qinan
- Target Recruit Count
- 60
- Registration Number
- NCT01435980
- Locations
- 🇨🇳
Endocrine Department, the south west Hospital of the Third Military Medical University, Chongqing, Chongqing, China
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 24
- Registration Number
- NCT01432405
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Impact of Exenatide on Sleep Duration
- Conditions
- Type 2 Diabetes
- First Posted Date
- 2011-08-15
- Last Posted Date
- 2023-04-26
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 8
- Registration Number
- NCT01416649
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
Changes in Bone Turnover With Exposure to a GLP-1 Receptor Agonist
- Conditions
- Bone RemodelingType 2 Diabetes Mellitus
- Interventions
- Drug: Saline
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 14
- Registration Number
- NCT01381926
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass
- Conditions
- Coronary Artery DiseaseDecreased Left Ventricular Function
- Interventions
- First Posted Date
- 2011-06-14
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Charles University, Czech Republic
- Target Recruit Count
- 38
- Registration Number
- NCT01373216
- Locations
- 🇨🇿
General University Hospital, Prague, Czech Republic
Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2023-07-12
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 23
- Registration Number
- NCT01364584
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.